The Australia medical cannabis market size reached USD 740.0 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,373.1 Million by 2033, exhibiting a growth rate (CAGR) of 7.10% during 2025-2033. The market is driven by increasing government approvals, rising patient demand for alternative treatments, expanding research on therapeutic benefits, and growing investment in domestic cannabis production. Improved accessibility, physician acceptance, and evolving regulations further contribute to the Australia medical cannabis market growth.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024 | USD 740.0 Million |
Market Forecast in 2033 | USD 1,373.1 Million |
Market Growth Rate 2025-2033 | 7.10% |
Increasing Government Approvals and Regulatory Support
The Australian government has progressively eased restrictions on medical cannabis, making it more accessible to patients. The Therapeutic Goods Administration (TGA) allows medical cannabis prescriptions under the Special Access Scheme (SAS) and Authorised Prescriber pathways, which is positively impacting the Australia medical cannabis market outlook. The expansion of legal frameworks has fueled doctor willingness to prescribe cannabis-based medicated treatments leading to industry development. The medical cannabis industry continues to advance through rules established at the state level which enhance patient access. The market is expected receive a boost from policymakers who understand cannabis' medical capabilities by quickly approving new products along with better regulations. Government support for Australia's medical cannabis industry will enhance both industrial development and medication distribution and technological advancements. For instance, in September 2024, a global leader in medical cannabis, Tilray Medical, a division of Tilray Brands, Inc., declared the introduction of Redecan EU-GMP-certified medical cannabis products in Australia. This partnership enables patients and healthcare professionals to make well-informed, personalized health decisions. Australia’s supportive regulatory framework is enabling more global medical cannabis brands to enter the market, reinforcing the trend of increased accessibility and acceptance of cannabis-based treatments.
Rising Patient Demand for Alternative Treatments
Patients suffering from chronic pain, epilepsy, anxiety, multiple sclerosis, and cancer-related symptoms are increasingly turning to medical cannabis as an alternative or complementary therapy. Traditional pharmaceuticals often come with side effects or limited effectiveness, leading many to seek cannabis-based treatments for pain relief, inflammation, and neurological conditions. Greater awareness of CBD (cannabidiol) and THC (tetrahydrocannabinol) benefits, along with patient advocacy, has driven demand, which is fueling the Australia medical cannabis market share. As more Australians explore natural, plant-based medicines, the demand for prescription cannabis products continues to surge, encouraging growth in the sector. This rising acceptance is prompting companies to scale operations and explore regional expansion to meet growing patient needs. For instance, in February 2025, Dispensed, a leading Australian medicinal cannabis company announced its plans to launch New Zealand operations, utilizing kiosks in various locations such as pharmacies and clinics. As patient trust in cannabis-based therapies continues to build, the sector is expected to see sustained momentum, reinforcing the upward trajectory of the Australia medical cannabis market.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the regional level for 2025-2033. Our report has categorized the market based on species, derivatives, application, route of administration, and end use.
Species Insights:
The report has provided a detailed breakup and analysis of the market based on the species. This includes indica, sativa, and hybrid.
Derivatives Insights:
A detailed breakup and analysis of the market based on the derivatives have also been provided in the report. This includes cannabidiol (CBD), tetrahydrocannabinol (THC), and others.
Application Insights:
A detailed breakup and analysis of the market based on the application have also been provided in the report. This includes cancer, arthritis, migraine, epilepsy, and others.
Route of Administration Insights:
A detailed breakup and analysis of the market based on the route of administration have also been provided in the report. This includes oral solutions and capsules, vaporizers, topicals, and others.
End Uses Insights:
A detailed breakup and analysis of the market based on the end uses have also been provided in the report. This includes the pharmaceutical industry, research and development centers, and others.
Regional Insights:
The report has also provided a comprehensive analysis of all the major regional markets, which include Australia Capital Territory & New South Wales, Victoria & Tasmania, Queensland, Northern Territory & Southern Australia, and Western Australia.
The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Million USD |
Scope of the Report |
Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment:
|
Species Covered | Indica, Sativa, Hybrid |
Derivatives Covered | Cannabidiol (CBD), Tetrahydrocannabinol (THC), Others |
Applications Covered | Cancer, Arthritis, Migraine, Epilepsy, Others |
Route of Administrations Covered | Oral Solutions and Capsules, Vaporizers, Topicals, Others |
End Uses Covered | Pharmaceutical Industry, Research and Development Centers, Others |
Regions Covered | Australia Capital Territory & New South Wales, Victoria & Tasmania, Queensland, Northern Territory & Southern Australia, Western Australia |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |